64 results about "Left ventricular ejection" patented technology

The invention provides a clinical diagnosis and treatment path generation method and system for tracking a chest pain patient. Wherein a dynamic spatio-temporal data atlas is constructed by synchronously collecting respiratory rhythm phase difference, coronary artery calcification integral and hypersensitive troponin curve slope, and risk degree transition signals are generated by coupling analysis of ST segment elevation amplitude asymmetric growth, left ventricular ejection fraction attenuation gradient and B-type natriuretic peptide release rate. In the acute stage, the constraint relation between a vascular recanalization time window and thrombolysis taboo is dynamically bound, in the subacute stage, a phase synchronization rule for enhancing CT scanning and anticoagulant drug dosage is established through a multidisciplinary interface, intravascular ultrasonic plaque morphological mutation characteristics and extracorporeal circulation parameters are fused, the blood supply reconstruction time sequence is dynamically adjusted based on a myocardial oxygen consumption balance equation, and the thrombolysis time sequence is determined. And path self-optimization is realized through space-time superposition of an interventional therapy delay parameter and a drug metabolism curve. According to the technical scheme provided by the invention, chest pain diagnosis and treatment path dynamic optimization and multi-modal parameter collaborative decision-making are realized, and the risk layering precision and the treatment timeliness are improved.

The invention provides a left heart data analysis method and system based on image segmentation, and relates to the technical field of medical image processing. Comprising the following steps: acquiring cardiac ultrasound image data and preprocessing; performing image segmentation on the preprocessed image data to obtain a segmentation result including a left ventricle, a left ventricular wall and a left atrium; searching a boundary line of the left ventricle and the left atrium, selecting two boundary points corresponding to the minimum and maximum abscissas in the boundary line as left and right mitral valve ring points respectively, and establishing a long axis based on the mitral valve ring midpoint and the cardiac apex point; modeling the ventricle into a structure formed by superposing a plurality of discs along the long axis direction, and obtaining the diameter of the corresponding disc; based on the obtained diameters of the corresponding discs, the left ventricular volumes in the diastolic period and the systolic period are calculated respectively, and the left ventricular ejection fraction is calculated. According to the method, image segmentation and geometric modeling are fused to achieve accurate calculation of the cardiac ejection fraction, meanwhile, the accuracy of cardiac structure image segmentation is improved, and an interpretable ejection fraction estimation process is achieved.

The invention provides application of a monascus composition in preparation of a medicine for preventing and / or treating coronary microcirculation disturbance. The monascus composition comprises one or more of cortex mori, ramulus mori and folium mori, monascus and radix puerariae. When the composition containing the red yeast rice is applied to preparation of the medicine for preventing and / or controlling coronary microcirculation disturbance, the abnormal microvascular structure can be improved (myocardial microvascular density MVD is increased, edema around microvessels is relieved, the lumen stenosis phenomenon is improved, and the endothelial cell condition is good); 2) microvascular occlusion is improved (pathologic results show that microvascular contents are reduced); (3) the abnormal vasodilatation and contraction function of the microvessels is improved (NO is increased); 4) improving blood lipid metabolism disorder; and (5) the heart function is improved (the left ventricular ejection fraction LVEF and the left ventricular short axis shortening rate LVFS are improved, and the left ventricular pressure maximum rising rate LV + dp / dtmax and the left ventricular pressure maximum falling rate LV-dp / dtmax are increased).

The invention relates to the field of biological medicine, in particular to application of S100A9 in treatment or detection of diabetic cardiomyopathy. The research finds that the expression of S100A9 in the heart tissue of a diabetic cardiomyopathy mouse is obviously increased. Overexpression of the S100A9 can aggravate myocardial injury and cardiac dysfunction, and inhibition of expression or activity of the S100A9 can improve illness conditions. Both the S100A9 inhibitor paquinimod and the macrophage scavenger chlorophosphonate liposome can reduce the concentration of S100A9 in serum, relieve cardiac enlargement and myocardial fibrosis and recover the left ventricular ejection fraction. In addition, the S100A9 can be used as a marker for detecting the diabetic cardiomyopathy, and related detection products can reflect the severity of the illness state by detecting the expression quantity of the S100A9 in tissue cells or body fluid. The invention provides a new target spot, medicine and detection means for treatment and detection of diabetic cardiomyopathy.

The invention discloses a self-adaptive control method and equipment based on an external counterpulsation device and a medium, and relates to the technical field of hemodynamics, and the method comprises the following steps: obtaining the gas inflation and deflation speed of the external counterpulsation device, carrying out air bag volume accumulation analysis on the gas inflation and deflation speed, and determining air bag volume data; based on the air bag volume data, through air bag pressure change analysis, blood vessel pressure data generated by the air bag on the limb is obtained; according to the blood vessel pressure data, the blood inflow amount of the left atrium is determined through blood backflow state analysis in the diastolic period; performing left ventricular ejection stroke-per-volume analysis on the left atrium blood inflow in a systolic period to obtain cardiac output data; based on cardiac output data or gas inflation and deflation speed, a self-adaptive regulation and control strategy of the in-vitro counterpulsation device is determined through real-time analysis of hemodynamic parameters. By means of the method, the problem that in the prior art, the external counterpulsation device cannot be adjusted in real time according to the current state of the user is solved.

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

The invention belongs to the technical field of medicines, and particularly relates to application of indole-3-propionic acid in preparation of a medicine for treating myocardial ischemia-reperfusion injury. A stable and reliable mouse MIRI model is successfully constructed through a coronary artery ligation left anterior descending branch reperfusion method, and it is found through indole-3-propionic acid (IPA) intervention and multi-dimensional evaluation that IPA administration can significantly improve the left ventricular ejection fraction LVEF and the left ventricular short-axis shortening rate LVFS of a model mouse, reduce the left ventricular end diastolic inner diameter LVEDd and the end systolic inner diameter LVESd, and significantly improve the model mouse left ventricular ejection fraction LVEF, the left ventricular end diastolic inner diameter LVEDd and the left ventricular end diastolic inner diameter LVESd. The heart function is effectively improved; the myocardial fibrosis area can be reduced, the mRNA expression of fibrosis-promoting and pathological hypertrophy-promoting molecules in myocardial tissues can be obviously reduced, and the myocardial injury progress can be inhibited in a multi-dimensional manner. The invention provides a brand new strategy for treating myocardial ischemia reperfusion injury, has important application value and wide clinical transformation prospect, and is expected to provide a new direction for clinical treatment.

The embodiment of the invention provides an in-aorta pressure reduction pump which comprises a diaphragm assembly capable of enabling liquid to flow in one direction and a pressure reduction pump, the pressure reduction pump is connected with the diaphragm assembly, and the flow directions of the pressure reduction pump and the diaphragm assembly are the same; the diaphragm assembly comprises a diaphragm body used for clamping the inner side of the aorta. In the direction of the axis of the diaphragm body, the outline of the pressure reduction pump is smaller than the size of the diaphragm body; the input end and the output end of the pressure reduction pump are located on the two sides of the plate face of the diaphragm body respectively. According to the technical scheme, the aorta is clamped through the diaphragm assembly, a buffer area can be formed outside the aortic valve, the buffer area can normally circulate during aorta ejection and is closed in the diastolic period, then a low-pressure area is formed in the buffer area in the diastolic period in a decompression pump extraction mode, the resistance of left ventricle ejection in the systolic period is reduced, and the cardiac effect is improved. And blood is prevented from flowing back through the incompletely closed aortic valve, so that the heart load is reduced, and the treatment effect is achieved.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

The invention discloses a motion intervention heart failure repair method based on Lgmn signal regulation and control, and relates to the technical field of heart failure treatment. According to the method, through aerobic exercise training (AET) with specific parameters, expression of Legumain (Lgmn) genes in macrophages is regulated in a targeted mode, the interburial effect of the macrophages is enhanced, then cell communication between the macrophages and cardiac muscle cells is enhanced, removal of the vertical death cardiac muscle cells is promoted, myocardial fibrosis and inflammatory response are relieved, and the effect of treating myocardial fibrosis is achieved. Finally, ventricular remodeling and heart functions of chronic heart failure (CHF) mice are improved. Experimental verification shows that the exercise intervention method can significantly improve the left ventricular ejection fraction (LVEF) and shortening fraction (FS) of CHF model animals, reduce the left ventricular end-of-systole inner diameter (LVESD), reduce myocardial cell apoptosis and necrosis, and promote inflammation regression. Drug intervention is not needed, safety is high, operation is easy and convenient, and a new effective way is provided for clinical rehabilitation treatment of heart failure.

The traditional Chinese medicine composition is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 3 to 9 parts of rhizoma chuanxiong, 3 to 7 parts of rhizoma atractylodis, 6 to 14 parts of rhizoma cyperi, 6 to 14 parts of medicated leaven, 3 to 7 parts of euphorbia helioscopia, 10 to 20 parts of poria cocos, 8 to 12 parts of fructus trichosanthis, 8 to 12 parts of radix salviae miltiorrhizae, 8 to 12 parts of herba epimedii, 3 to 9 parts of pepper, 8 to 12 parts of herba patriniae and 8 to 12 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating acute myocardial infarction, a remarkable effect is achieved on PCI postoperative improvement of acute myocardial infarction, troponin and creatine kinase isoenzyme indexes are reduced, and the left ventricular ejection fraction is in a normal range after cardiac color ultrasound display treatment. Through comprehensive conditioning, symptoms such as chest distress, chest pain, shortness of breath and hypodynamia of patients are improved, cardiac function recovery is promoted, complications such as restenosis and heart failure are prevented, and life quality is improved.

The invention relates to the technical field of medicines, in particular to application of an AKT inhibitor targeting FOXO in preparation of a medicine for promoting myocardial ischemic tissue angiogenesis and application of the AKT inhibitor in preparation of a medicine for treating ischemic heart diseases. In the cell level, the AKT inhibitor Ipatasertib can promote migration and tube formation of the HUVEC, and when the 6 [mu] M of Ipatasertib acts on the HUVEC, the expression of AKT can be significantly reduced, and the phosphorylation level of FOXO3 can be inhibited. In an in-vivo experiment, compared with a model group, a mouse in an Ipatasertib intervention group has the advantages that the left ventricular ejection fraction of an echocardiogram is remarkably increased, the myocardial infarction area is remarkably reduced, and the fluorescence density of an angiogenesis marker CD31 + is remarkably increased, so that the Ipatasertib can promote angiogenesis of a myocardial ischemia region of the mouse with acute myocardial infarction and rescue myocardial injury of the mouse.

Described herein is an apparatus and a method for left ventricular ejection fraction (LVEF) prediction. An apparatus may include at least a processor, and a memory communicatively connected to the at least processor, wherein the memory contains instructions configuring the at least processor to receive a first electrocardiogram (ECG) datum; input the first ECG datum into an LVEF prediction model; and receive as an output from the LVEF prediction model a first LVEF prediction.

The invention provides a method for measuring the left ventricular ejection fraction of a dynamic echocardiography. The method comprises the following steps: inputting a to-be-identified echocardiogram sequence into a neural network segmentation model based on multi-frame feature aggregation, then performing spatial feature coding on each frame of image of the to-be-identified echocardiogram sequence through a spatial feature encoder structure to obtain a spatial feature map corresponding to each frame of image, and finally, identifying the to-be-identified echocardiogram sequence according to the spatial feature map. Performing cross-frame and cross-section spatio-temporal feature aggregation on the spatial feature pattern through a spatio-temporal feature aggregation structure to obtain global spatio-temporal features including time sequence information of a heart apex two-cavity section and a heart apex four-cavity section; the left ventricular ejection fraction determining method comprises the steps of generating a left ventricular membrane segmentation mask of a terminal diastole frame and a terminal systole frame on the basis of global spatial-temporal characteristics and spatial shallow layer characteristics corresponding to the terminal diastole frame and the terminal systole frame, and finally determining the left ventricular ejection fraction on the basis of the left ventricular membrane segmentation mask of the terminal diastole frame and the terminal systole frame.

The invention relates to the technical field of medicine, in particular to a composition containing an angiotensin II receptor blocker and application of the composition in heart disease dilation medicine. The composition comprises an angiotensin converting enzyme inhibitor and an angiotensin II receptor blocker, and a small dose of ACEI and a large dose of ARB are combined to be used for dilating the heart disease. The traditional Chinese medicine composition has excellent effects in the aspects of reducing the left ventricular end diastolic anterior-posterior diameter or left-right diameter, plasma brain natriuretic peptide precursor (NT-pro BNP) plasma level, pulmonary arterial pressure and left ventricular ejection fraction, does not influence the normal levels of physiological indexes such as blood potassium, serum creatinine, urea nitrogen, alanine aminotransferase (ALT) and asparaginic acid aminotransferase (AST), and can be used for preparing a medicine for treating the left ventricular end diastole. The medicine can be applied to heart disease dilation medicines.

According to the left ventricular ejection fraction continuous prediction method based on the II-lead electrocardiogram, continuous regression prediction from single-lead electrocardiosignals to EF numerical values is achieved by constructing a deep neural network model fusing a convolutional neural network (CNN) and a long-short-term memory network (LSTM), and the method has the advantages of being easy and convenient to collect, accurate in prediction and flexible in deployment and has good application prospects. The continuous non-invasive prediction of the EF can be realized, the dependence on equipment, artificial experience and operation environment in the prior art is overcome, and a brand new solution is provided for bedside dynamic cardiac function monitoring. And the method has remarkable medical practical value and industrial transformation prospect.

The invention discloses a left ventricular ejection fraction regression prediction system based on transfer learning and multi-view fusion, and belongs to the field of medical image analysis. The problem that an existing deep learning method is poor in left ventricular ejection fraction prediction accuracy is solved. According to the method, the A4C view angle echocardiogram data and the PSAX view angle echocardiogram data are subjected to independent model pre-training, and then the pre-trained model parameters are subjected to transfer learning, so that a better initialization effect can be obtained, and model convergence and performance optimization are accelerated. The double-view-angle fusion regression module can well combine spatial and temporal features output by the two single-view-angle models, feature relevance of echocardiogram data of the two view angles is greatly utilized, and the accuracy of final model prediction can be improved. In addition, through fusion of the multi-view echocardiogram data features, the influence of anatomical structure differences on the detection result is effectively reduced. The method can be applied to left ventricular ejection fraction regression prediction.

The invention discloses a method for predicting heart failure based on left ventricular ejection fraction, which develops and trains a primitive model to automatically provide help and evaluate the level of clinical decision based on LVEF heart failure. The training model is prevented from using any or biased clinical variables, and the following two steps are ensured: investigating the statistical significance of each variable to distinguish the three categories; secondly, a novel dimension reduction technology is adopted to visually observe the characterization of the optimal variable in the radial direction, and each LVEF-based HF category is separated; and on the basis, the performance of the developed model is trained, the importance of the most important clinical variables is discussed, and the significance of the clinical variables is explained in detail based on the application of LVEF-based deep learning in HF analysis, so that patient data of three heart failure types are distinguished.

The invention belongs to the field of new application of medicines, and particularly relates to application of Oloinab in preparation of medicines for treating and / or preventing ischemic cardiomyopathy. Animal experiments prove that Oloinab can remarkably improve the left ventricular ejection fraction and the left ventricular short axis shortening rate of myocardial infarction model mice, improve the heart function and reduce the cardiac fibrosis area, and it is indicated that Oloinab has the effect of improving myocardial remodeling and systolic dysfunction. The discovery provides a new treatment strategy for ischemic cardiomyopathy, and has an important clinical application prospect.

This application provides an ultrasound cardiac dynamic monitoring system and method, relating to the field of ultrasound cardiac function dynamic monitoring technology. The system includes: a patch-type ultrasound probe, a hydrogel patch, a wearable hardware module, and a cardiac function analysis module. The cardiac function analysis module is configured to: receive the ultrasound image; determine a target sampling line in the ultrasound image based on a reinforcement learning model; control the wearable hardware module to acquire M-mode images along the target sampling line; input the M-mode images into a deep learning model to output the key point positions of the left ventricular septum and the left ventricular posterior wall at end-diastole and end-systole based on the deep learning model; calculate the left ventricular ejection fraction (LVEF) based on the LVEF and the key point positions; the LVEF represents the dynamic monitoring and detection results of cardiac function. This system can improve the effectiveness and accuracy of dynamic cardiac monitoring.

The present invention discloses a traditional Chinese medicine preparation for preventing and / or treating myocardial infarction, its preparation method and application, belonging to the technical field of pharmaceuticals. The traditional Chinese medicine is obtained by extracting Areca catechu with 20% - 95% ethanol. The present invention first reveals that the Areca catechu extract has an anti-myocardial infarction effect. The experimental results show that the crude extract of Areca catechu can significantly inhibit H2O2-induced cardiomyocyte death, improve the left ventricular ejection fraction of myocardial infarction mice, and reduce the myocardial infarction area, and the effect is equivalent to that of the positive drug Suxiao Jiuxin Pills, while arecoline has no cardiomyocyte protection effect. The present invention is of natural origin, simple to prepare, and low in cost, and can be used as a new supplement or alternative for clinical prevention and treatment of myocardial infarction, and has important clinical value and application prospects.

The present application relates to a method for determining whether an object has heart failure or is at risk of developing heart failure, particularly heart failure with reduced left ventricular ejection fraction (HFREF) and heart failure with preserved left ventricular ejection fraction (HFPEF). The method comprises determining the level of a selected miRNA observed in a sample obtained from the object, and wherein a change in the level of the miRNA compared to a control indicates that the object has heart failure or is at risk of developing heart failure. The invention also includes a method for determining a change in the risk of death or disease progression to hospitalization and death based on a change in a selected miRNA in a sample obtained from the object, and a kit thereof.

Embodiments of the present disclosure provide a left ventricular ejection fraction prediction method, device, equipment, medium and product. The method comprises: acquiring a heart ultrasound sequence of a heart part; inputting the heart ultrasound sequence into a target processing model trained in advance to output a left ventricular graph sequence which has been marked with a left ventricle; determining a plurality of effective image pairs according to area change rates of a plurality of left ventricular segmentation images in the left ventricular graph sequence, and determining left ventricular end-diastolic volumes and left ventricular end-systolic volumes corresponding to each effective image pair; and determining a left ventricular ejection fraction according to the left ventricular end-diastolic volumes and the left ventricular end-systolic volumes associated with the plurality of effective image pairs. The technical solution of the embodiments of the present disclosure processes the heart ultrasound sequence based on the target processing model to determine the left ventricular ejection fraction, which can weaken the influence of factors such as poor single-frame quality, respiratory jitter and arrhythmia, thereby achieving the effect of improving the accuracy of the left ventricular ejection fraction.

The invention discloses a heart ultrasound video left ventricle segmentation and ejection fraction calculation method based on a DeepLabv3 + and R (2 + 1) D network, and belongs to the field of medical artificial intelligence. The method aims at solving the problems that in the prior art, left ventricle function evaluation time sequence information is insufficient in utilization, the key frame recognition automation degree is low, and the segmentation precision and the overall process automation degree are not high. According to the technical scheme, the method comprises the following steps: preprocessing an original cardiac ultrasound video, including frame extraction, intelligent cutting of a region of interest and data enhancement; performing time sequence modeling on a video sequence by using an R (2 + 1) D network, and automatically identifying key frames of the end of diastole (ED) and the end of systole (ES); performing high-precision pixel-level left ventricle region segmentation on the identified key frame by adopting a DeepLabv3 + network; estimating a left ventricular end diastolic volume (LVEDV) and a left ventricular end systolic volume (LVESV) by combining an improved Simpson method on the basis of a segmentation result and image physical size calibration information; and finally, calculating a left ventricular ejection fraction (LVEF) according to a standard formula, and outputting a structured report and a visual image. Through multi-network collaboration and full-process automation, the accuracy, efficiency, objectivity and consistency of LVEF evaluation are remarkably improved, and the method has a good clinical application prospect.

The application discloses a new application of 3-HPPA in preparing a drug for treating myocardial infarction. By means of modern pharmacological research methods, it is first confirmed that 3-HPPA has a significant myocardial protective effect. Experimental research shows that 3-HPPA can significantly improve the heart function of a myocardial infarction mouse induced by coronary artery ligation, improve the left ventricular ejection fraction and the short axis shortening rate, and reduce the infarction area; meanwhile, 3-HPPA can significantly inhibit the gene expression of a heart failure marker BNP, and down-regulate the expression levels of inflammatory factors IL-6, TNF-alpha and fibrosis related factors TGF-beta and Collagen I. Further mechanism research shows that 3-HPPA also plays an anti-inflammatory, anti-fibrosis and anti-apoptosis role. The application discloses the action characteristics of 3-HPPA in multi-target intervention of the pathological process of myocardial infarction, provides an important candidate compound for development of a new type of anti-myocardial infarction drug, and has a wide clinical application prospect.

The invention belongs to the field of biological materials and cardiovascular repair, and relates to hydrogel for repairing after myocardial infarction as well as a preparation method and application of the hydrogel. The hydrogel consists of chitosan or a derivative thereof, silk fibroin, tannic acid and a biological cross-linking agent in a weight ratio of 3: (0.8-1.2): (0.1-3.0): (0.1-0.2). According to the invention, tannic acid is introduced into the chitosan-silk fibroin composite hydrogel as a cross-linking agent and a rigidity reinforcing agent, so that the compressive strength of the hydrogel is increased from 34.4 kPa to 84.45 kPa, and the elastic modulus is increased to gt; and the mechanical property of the material is matched with that of the myocardial tissue. Meanwhile, the hydrogel can realize multi-dimensional coordinated regulation and control on oxidative stress, inflammatory response and myocardial fibrosis: in a myocardial infarction model, the hydrogel enables the left ventricular ejection fraction (LVEF) to be increased by 25%, the active oxygen clearance rate to be increased by 45%, the inflammatory cell infiltration to be reduced by 45%, the proinflammatory cytokine (IL-6 / TNF-alpha) level to be reduced by 30%, and the fibrosis area to be reduced by 40%; therefore, the heart failure process after myocardial infarction is effectively delayed.

[Problem] To provide a program, an information processing method, an information processing system, and the like with which it is possible to detect HFpEF early. [Solution] According to one aspect of the present invention, there is provided a program configured to cause a computer to execute an acquisition step, a calculation step, and an output step. In the acquisition step, first electrocardiogram data for a first subject is acquired. In the calculation step, an index corresponding to HFpEF, which is one of the phenotypes of heart failure classified by the left ventricular ejection fraction, and an index corresponding to the expected value of the left ventricular ejection fraction are calculated on the basis of the first electrocardiogram data and reference information. The reference information indicates the relationship between second electrocardiogram data for a second subject and the indexes. In the output step, the calculated indexes are outputted. The index corresponding to HFpEF is at least one from among the probability that HFpEF has developed, an expected value calculated from the probability, and information obtained by scaling the expected value to a prescribed range.

The invention relates to application of nervonic acid to preparation of a medicine for preventing and treating pressure overload pathological cardiac hypertrophy. Through in-vivo animal research, the inventor finds that nervonic acid can improve the left ventricular ejection fraction of the heart of a mouse with overload pressure, reduce the ventricular septum thickness and the left ventricular posterior wall thickness, reduce the ratio of the heart weight to the tibia length, reduce the cross sectional area of cardiac muscle cells, relieve cardiac fibrosis and reduce transcription of fibrosis related genes Tgfb1, Col1a1 and Col3a1. The nervonic acid is expected to become a candidate substance for preparing a medicine for preventing and treating the pressure overload pathological cardiac hypertrophy, and has a good clinical application prospect.

The invention discloses a main artery elastic reservoir simulation device, and relates to the technical field of medical teaching equipment. The device comprises a simulation left ventricle unit and a simulation right ventricle unit, wherein the simulation left ventricle unit is composed of a balloon capable of absorbing water and compressing and jetting water; the interior of the auxiliary part is composed of an adjusting pipe; and the simulated aorta unit is a main pipeline, and one end of the main pipeline is connected with the right side of the auxiliary component. Compared with the prior art, the device has the advantages that by simulating the processes of left ventricular ejection and main artery elastic retraction and comparing the elastic hose and the non-elastic hard tube, the action mechanism of the main artery blood vessel elastic storage device in the heart ejection process can be visually and vividly displayed, the abstract physiological process is converted into visual demonstration, and the demonstration efficiency is improved. And students are helped to understand related knowledge of blood circulation in cardiac physiology.

The invention provides application of gamma-linolenic acid in preparation of a medicine for preventing or treating diabetic cardiomyopathy. In-vivo and in-vitro experimental results show that the gamma-linolenic acid has a better effect in diabetic cardiomyopathy, which is mainly reflected in reducing oxidative stress (reducing lipid peroxidation), increasing expression of GSH and HO-1, reducing expression of MDA and Nrf2, increasing left ventricular ejection fraction (LVEF) and shortening fraction (FS), and repairing myocardial interstitial fibrosis. Therefore, the gamma-linolenic acid has the potential of being developed into the medicine for treating the diabetic cardiomyopathy.